Change to Your Diabetes/Heart Failure/Chronic Kidney Disease Medication
To align with NHS England guidance, we wish to inform our patients about a recommended change to your sodium-glucose co-transporter-2 inhibitors (SGLT2i medication, also known as “flozins”). This includes Forxiga, empagliflozin, canagliflozin, ertugliflozin to generic dapagliflozin.
Dapagliflozin is already the most prescribed SGLT2i nationally. NHS England has recommended that Integrated Care Boards (ICBs) support switching from other SGLT2i to generic dapagliflozin for cost effective prescribing.
Following a routine review of patient treatment for Diabetes, Heart Failure and Chronic Kidney Disease and in line with updated Cornwall ICB guidance, we will be switching those who are currently taking, Empagliflozin, Canagliflozin or Ertugliflozin, (“flozins”) to the recommended preferred formulary choice dapagliflozin Dapagliflozin: a medicine used to treat type 2 diabetes – NHS.
Why Are We Recommending This Change?
Your clinical team is switching your current medicine to one called Dapagliflozin.
The change ensures you continue to receive high-quality treatment while helping the NHS manage resources effectively.
Dapagliflozin belongs to the same family of medicines as your previous treatment and is just as effective.
This medicine provides the same health benefits but is more cost-effective, allowing the NHS to use its budget more efficiently for everyone.
Your healthcare specialist has specifically reviewed your records to ensure this switch is safe and the right choice for your ongoing care.
What Do You Need to Do?
We will arrange for your prescription to be updated to dapagliflozin and send through a new prescription to your pharmacy. Please note the milligrams will be different to what you were previously prescribed as it will be switched to a licensed equivalent dapagliflozin dosage.
If you have concerns about this change, or if you’ve experienced side effects with dapagliflozin in the past, please contact us to discuss further using an online consultation. (link to practice online triage)
Safeguarding Your Health
Long term condition annual reviews are standard practice to ensure safety and effectiveness. All patients on these medicines need at least an annual blood test and weight check to ensure the dose prescribed is safe and appropriate for you. This switch aligns with that process.
No additional monitoring is required beyond your usual check-ups.
Further information can be found at the following link.
37-A4-Dapagliflozin-switching-PIL-for-all-indications-SCN-March-2026.pdf